Brachytherapy in the therapy of prostate cancer - an interesting choice
- PMID: 24596528
- PMCID: PMC3934024
- DOI: 10.5114/wo.2013.38557
Brachytherapy in the therapy of prostate cancer - an interesting choice
Abstract
Brachytherapy is a curative alternative to radical prostatectomy or external beam radiation [i.e. 3D conformal external beam radiation therapy (CRT), intensity-modulated radiation therapy (IMRT)] with comparable long-term survival and biochemical control and the most favorable toxicity. HDR brachytherapy (HDR-BT) in treatment of prostate cancer is most frequently used together with external beam radiation therapy (EBRT) as a boost (increasing the treatment dose precisely to the tumor). In the early stages of the disease (low, sometimes intermediate risk group), HDR-BT is more often used as monotherapy. There are no significant differences in treatment results (overall survival rate - OS, local recurrence rate - LC) between radical prostatectomy, EBRT and HDR-BT. Low-dose-rate brachytherapy (LDR-BT) is a radiation method that has been known for several years in treatment of localized prostate cancer. The LDR-BT is applied as a monotherapy and also used along with EBRT as a boost. It is used as a sole radical treatment modality, but not as a palliative treatment. The use of brachytherapy as monotherapy in treatment of prostate cancer enables many patients to keep their sexual functions in order and causes a lower rate of urinary incontinence. Due to progress in medical and technical knowledge in brachytherapy ("real-time" computer planning systems, new radioisotopes and remote afterloading systems), it has been possible to make treatment time significantly shorter in comparison with other methods. This also enables better protection of healthy organs in the pelvis. The aim of this publication is to describe both brachytherapy methods.
Keywords: HDR brachytherapy; LDR brachytherapy; prostate cancer; seeds.
Similar articles
-
High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.Radiother Oncol. 2019 Mar;132:162-170. doi: 10.1016/j.radonc.2018.10.020. Epub 2018 Nov 8. Radiother Oncol. 2019. PMID: 30416045
-
Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16. doi: 10.1016/j.ijrobp.2014.11.018. Epub 2015 Jan 13. Int J Radiat Oncol Biol Phys. 2015. PMID: 25596107
-
Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1219-1229. doi: 10.1016/j.ijrobp.2020.11.023. Epub 2020 Dec 3. Int J Radiat Oncol Biol Phys. 2021. PMID: 33279595
-
[Brachytherapy in men with prostate cancer: update on indications and outcomes].Urologia. 2013 Apr-Jun;80(2):87-98. doi: 10.5301/RU.2013.11285. Epub 2013 Jul 1. Urologia. 2013. PMID: 23852925 Review. Italian.
-
Low-dose rate brachytherapy for men with localized prostate cancer.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008871. doi: 10.1002/14651858.CD008871.pub2. Cochrane Database Syst Rev. 2011. PMID: 21735436 Review.
Cited by
-
Psychosexual experiences of men following radiotherapy for prostate cancer in Johannesburg, South Africa.Health SA. 2018 Oct 9;23:1057. doi: 10.4102/hsag.v23i0.1057. eCollection 2018. Health SA. 2018. PMID: 31934370 Free PMC article.
-
The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer.J Contemp Brachytherapy. 2014 Oct;6(3):282-8. doi: 10.5114/jcb.2014.45586. Epub 2014 Sep 23. J Contemp Brachytherapy. 2014. PMID: 25337130 Free PMC article.
-
SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis.J Contemp Brachytherapy. 2018 Dec;10(6):577-582. doi: 10.5114/jcb.2018.81001. Epub 2018 Dec 28. J Contemp Brachytherapy. 2018. PMID: 30662483 Free PMC article.
-
Serum Paraoxonase-1 Activity in Prostate Cancer Patients Treated with Brachytherapy as a Measure of Irradiation Efficacy.Antioxidants (Basel). 2023 Jan 17;12(2):212. doi: 10.3390/antiox12020212. Antioxidants (Basel). 2023. PMID: 36829771 Free PMC article.
-
Attitude and practice of brachytherapy in India: a study based on the survey amongst attendees of Annual Meeting of Indian Brachytherapy Society.J Contemp Brachytherapy. 2015 Dec;7(6):462-8. doi: 10.5114/jcb.2015.55666. Epub 2015 Nov 17. J Contemp Brachytherapy. 2015. PMID: 26816503 Free PMC article.
References
-
- National Cancer Register Oncology Centre in Warsaw (access: 15.12.2011 – http://85.128.14.124/krn/).
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol. 2005;56:379–96. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials